Supragen wants to developing drugs and vaccines around a class of proteins called superantigens, which can trigger a massive immune response so strong it can induce toxic shock syndrome and may be part of the pathogenesis of other autoimmune, inflammatory and infectious diseases.
You may also be interested in...
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Can "real world evidence" drive consumer health innovation? HBW Insight speaks to Orbital Research’s Chris Bunniss about RWE’s potential for the OTC industry.
Italy's Chiesi is looking to take a slice of Poland's consumer healthcare market by acquiring infant supplements specialist Smart Pharma.